http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Shuai Hao,Wuguo Tian,Jianjie Zhao,Yi Chen,Xiaohua Zhang,Bo Gao,Yujun He,Donglin Luo 한국유방암학회 2020 Journal of breast cancer Vol.23 No.4
Purpose: Real-time detection and intervention can be used as potential measures to markedly decrease breast cancer mortality. Assessment of circulating tumor DNA (ctDNA) may offer great benefits for the management of breast cancer over time. However, the use of ctDNA to predict the effectiveness of neoadjuvant treatment and recurrence of breast cancer has rarely been studied. Methods: We prospectively recruited 31 breast cancer patients with 4 subtypes. Three time points were set in this study, including before any therapy (C1), during surgery (T), and six months after surgery (C2). We collected peripheral blood samples from all 31 patients at C1, tumor tissue from all 31 patients at T, and peripheral blood samples from 25 patients at C2. Targeted 727-gene panel sequencing was performed on ctDNA from all blood samples and tissue DNA from all tissue samples. Somatic mutations were detected and analyzed using a reference standard pipeline. Statistical analysis was performed to identify possible associations between ctDNA profiles and clinical outcomes. Results: In total, we detected 159, 271, and 70 somatic mutations in 30 C1 samples, 31 T samples, and 12 C2 samples, respectively. We identified specific genes, such as PIK3CA, TP53, and KMT2C, which were highly mutated in the tissue samples. Furthermore, mutated KMT2C observed in ctDNA of the C2 samples may be an indicator of breast cancer recurrence. Conclusion: Our study highlights the potential of ctDNA analysis at different timepoints for assessing tumor progression and treatment effectiveness, as well as prediction of breast cancer recurrence.
He Jia,Shao Xiaoqiang,Su Qin,Zhao Donglin,Feng Shaojie,오원춘 한국세라믹학회 2023 한국세라믹학회지 Vol.60 No.1
A series of novel cobalt ion-doped ZnCr2−xCoxO4 (x = 0, 0.1, 0.15, 0.2) spinel oxides were synthesized with the hydrothermal method. X-ray diffraction, scanning electron microscope, specific surface area, Raman spectroscopy, X-ray photoelectron spectroscopy, temperature-programmed desorption of oxygen, and other analytical techniques were used to characterize the structure, morphology, and catalytic performance of each sample. Experiment results showed that the doping of cobalt ion significantly promoted the phase crystallization of spinel oxide. Cobalt ion-doped ZnCr2−xCoxO4 (x = 0.1, 0.15, 0.2) nanoparticles with high specific surface area were synthesized at 773 K, with ZnCr2O4 forming a spinel phase at 1173 K. Catalytic experiments revealed that the catalytic activity of ZnCr2−xCoxO4 was effectively improved. Cobalt ion-doped ZnCr1.85Co0.15O4 catalyst catalyzed methane combustion reaction temperature at T90% (the temperature where 90% of methane was converted) of about 573 K, while the undoped ZnCr2O4 sample had the highest catalytic performance at T90% of about 773 K. The order of catalytic activity was: ZnCr1.85Co0.15O4 > ZnCr1.9Co0.1O4 > ZnCr1.8Co0.2O4 > ZnCr2O4. Results of catalytic experiments showed that the surface area of the catalyst increased after partial replacement of chromium ions by cobalt ions and that the increase in surface area of the catalyst provided more active sites, thus improving the reaction activity.
Shuai Hao,Miao Huang,Wuguo Tian,Yi Chen,Jianjie Zhao,Donglin Luo 한국유방암학회 2020 Journal of breast cancer Vol.23 No.6
Male breast cancer (MBC) is rare and accounts for approximately 1% of all breast cancer cases worldwide. Previous studies have suggested that several factors significantly increase the risk of MBC. Prolactinoma has the highest incidence rate among patients with functional pituitary tumors. However, whether prolactinoma is involved in the onset and progression of breast cancer remains unclear. To date, there are only five case reports globally on MBC with concurrent prolactinoma. We hereby describe the first case of MBC with prolactinoma in China. We also explored the patient's genetic profile using whole exome sequencing. Our findings may help advance our understanding of the molecular pathogenesis of MBC. Further molecular analyses of such cases are warranted to improve auxiliary molecular diagnostic methods and targeted therapy for MBC.
Jingcui Yu,Songbin Fu,Peng Liu,Xiaobo Cui,Yu Sui,Guohua Ji,Rongwei Guan,Donglin Sun,Wei Ji,Fangli Liu,An Liu,Yuzhen Zhao,Yang Yu,Yan Jin,Jing Bai,Jingshu Geng,Yingwei Xue,Jiping Qi,Ki-Young Lee 한국분자세포생물학회 2011 Molecules and cells Vol.32 No.1
Previously, we identified 3 overlapping regions showing loss of heterozygosity (LOH, R_1-R_3 from 11 to 30 cM) on chromosome 17 in 45 primary gastric cancers (GCs). The data indicated the presence of tumor suppressor genes (TSGs) on chromosome 17 involved in GC. Among the putative TSGs in these regions, HIC1 (in SR_1) and TOB1 (in SR_3) remain to be examined in GC. By immunohistochemistry (IHC), methylation-specific PCR (MSP) and western blot, we evaluated the expression and regulation status for HIC1 and TOB1 protein in GC. We narrowed down the deletion intervals on chromosome 17 and defined five smaller LOH subregions, SR_1-SR_5 (0.54 to 3.42 cM), in GC. We found that HIC1 had downregulated expression in 86% (91/106) and was methylated in 87% (26/30) of primary GCs. Of the primary GCs showing downregulation of HIC1 protein, 75% (18/24) had methylated HIC1 gene. TOB1 was either absent or expressed at reduced levels in 75% (73/97) of the GC samples. In addition, a general reduction was found in total and the ratio of unphosphorylated to phosphorylated TOB1 protein levels in the differentiated GC cell lines. Further analysis revealed significant simultaneous downregulation of both HIC1 and TOB1 protein in GC tissue microarray samples (67%, 52/78) and in primary GCs (65%, 11/17). These results indicate that silencing of HIC1 and TOB1 expression is a common occurrence in GC and may contribute to the development and progression of the disease.